UC Irvine
Welcome,         Profile    Billing    Logout  
 37 Trials 
90 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Potkin, Steven
NCT01987050: Intranasal Oxytocin in Schizophrenia Patients

 
3
71
US
Intranasal oxytocin
University of California, Irvine, National Institute of Mental Health (NIMH), University of California, San Diego
Schizophrenia
09/14
 
Hermanowicz, Neal
NCT03515213: Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

Completed
2a
10
US
Fenofibrate, Placebo
University of California, Irvine
Huntington Disease
08/21
08/21
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
Goyal, Namita
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
COMBAT-ALS, NCT04057898 / 2019-003549-14: Evaluation of MN-166 (ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with ALS

Recruiting
2/3
230
Canada, US
MN-166, ibudilast, placebo
MediciNova
Amyotrophic Lateral Sclerosis
12/25
12/26
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Recruiting
1/2
20
US
AMT-162
UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
09/26
03/31
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 
CAPTURE, NCT03489278: Clinical Procedures to Support Research in ALS

Recruiting
N/A
1200
US
University of Miami, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
06/25
06/25
INSPIRE-IBM, NCT05046821: Sporadic Inclusion Body Myositis Natural History Study

Active, not recruiting
N/A
150
US
University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
01/26
01/26
Mozaffar, Tahseen
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Active, not recruiting
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences, LLC
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
03/25
03/26
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Active, not recruiting
2
12
Europe, US, RoW
Daxdilimab, HZN-7734, Placebo
Amgen
Idiopathic Inflammatory Myositis
03/25
10/25
RESET-Myositis, NCT06154252: an Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Recruiting
1/2
24
Europe, US
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Cabaletta Bio
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
07/28
07/28
NCT05517603: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Completed
1/2
25
US
AJ201, JM17, Placebo
AnnJi Pharmaceutical Co., Ltd.
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
04/24
04/24
FORTIS, NCT04174105: Gene Transfer Study in Patients With Late Onset Pompe Disease

Recruiting
1/2
18
Europe, US
zocaglusagene nuzaparvovec, AT845
Astellas Gene Therapies
Pompe Disease (Late-onset)
11/29
11/29
LION-CS101, NCT05230459: A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Recruiting
1/2
10
US
AB-1003 dose level 1, AB-1003 dose level 2, Placebo
Asklepios Biopharmaceutical, Inc.
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
12/28
12/28
NCT04093349 / 2019-001283-30: A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Active, not recruiting
1/2
4
Europe, Canada, US
SPK-3006
Spark Therapeutics, Inc.
Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II, LOPD, Lysosomal Storage Diseases, Acid Maltase Deficiency
04/32
04/32
GRASP-01-002, NCT05257473: Defining Endpoints in Becker Muscular Dystrophy

Recruiting
N/A
80
Europe, US, RoW
Virginia Commonwealth University, Edgewise Therapeutics, Inc.
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
05/25
05/26
GRASP, NCT03981289: Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Active, not recruiting
N/A
80
Europe, US
Virginia Commonwealth University, Newcastle University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Minnesota, University of California, Irvine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Colorado, Denver, University of Kansas Medical Center
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
06/25
06/25
INSPIRE-IBM, NCT05046821: Sporadic Inclusion Body Myositis Natural History Study

Active, not recruiting
N/A
150
US
University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
01/26
01/26
GRASP-01-003, NCT05618080: LGMD R1 Natural History Study

Recruiting
N/A
100
Europe, US
Virginia Commonwealth University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Florida, University of Minnesota, Newcastle University, University of Kansas Medical Center, University of Colorado, Denver, Indiana CHC (Community Health Clinic), University of California, Irvine
Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
05/28
08/28
Jeyakumar, Deepa
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
NCI-2019-03057, NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Active, not recruiting
2
14
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
01/24
11/25
A041703, NCT03739814: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
2
64
US
Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Inotuzumab Ozogamicin, Besponsa, CMC 544, CMC-544, CMC544, Way 207294, WAY-207294
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
02/25
02/25
NCT04231851: CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Active, not recruiting
2
30
US
Glasdegib, DAURISMO™, CPX-351, Daunorubicin and cytarabine, VYXEOS®
University of California, Irvine, Jazz Pharmaceuticals, Pfizer
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
06/25
06/27
NCI-2019-08626, NCT04214249: BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active, not recruiting
2
48
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Echocardiography, EC, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, HEMATOPOIETIC STEM CELL TRANSPLANT, Hematopoietic Stem Cell Transplantation, HSCT, SCT, Stem Cell Transplant, stem cell transplantation, Stem Cell Transplantation, NOS, Idarubicin Hydrochloride, Idamycin, Idamycin PFS, Idarubicin HCl, IMI-30, SC-33428, Zavedos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
11/24
01/26
NCT05600894: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recruiting
2
132
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
08/25
08/25
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
NCT04764474: A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Recruiting
1
75
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
09/24
06/25
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT05501899: Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Recruiting
1
20
US
Levocarnitine, Carnitor®
Children's Hospital of Orange County, University of California, Irvine
Acute Lymphoblastic Leukemia, Hepatotoxicity
12/24
12/24
NCT06146257: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Recruiting
1
48
US
GLB-001, GLB-C183-A-2
GluBio Therapeutics Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
10/26
UCHMC 1812, NCT03904251: CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Checkmark From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Nov 2020 - Nov 2020: From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Terminated
1
13
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos
Jonsson Comprehensive Cancer Center, Pfizer, Jazz Pharmaceuticals, University of California, Los Angeles
Acute Myelogenous Leukemia
10/23
10/23
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML with Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
Park, Hannah
NCT04962529: Breast Cancer Liquid Biopsy Trial

Recruiting
N/A
450
Canada, US
Blood Draw
Anthony Magliocco, Epic Sciences, DHR Health Institute for Research and Development, Memorial Healthcare System, University of Saskatchewan, Florida Cancer Specialist, Montefiore Medical Center, Ocala Oncology, NY Health d/b/a New York Cancer and Blood Specialists, Northwest Community Healthcare
Breast Cancer, Cancer
06/23
07/23
NCT06518798: Feasibility and Preliminary Effects of Fasting-Mimicking Diet in Asian Americans With Prediabetes

Recruiting
N/A
30
US
Fasting Mimicking Diet
University of California, Irvine, University of Southern California
Prediabetes, Prediabetic State
11/24
12/24
WISDOM, NCT02620852: Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Recruiting
N/A
100000
US
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
University of California, San Francisco, Patient-Centered Outcomes Research Institute, Robert Wood Johnson Foundation, Color Genomics, Inc., Salesforce, National Cancer Institute (NCI), Safeway Foundation, United States Department of Defense
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
09/25
09/25
NCT04962191: Idylla EGFR Lung Trial

Recruiting
N/A
150
US
Idylla EGFR Mutation Test
Anthony Magliocco
Lung Cancer, Technology, Oncology
12/22
01/23
Martin, Veronica
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Dayyani, Farshid
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Recruiting
4
78
US
Fruquintinib, Fruzaqla™
Takeda
Colorectal Cancer
02/28
02/28
A022102, NCT05677490: MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
3
382
US
Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC V8, Clinical Stage III Gastric Cancer AJCC V8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IV Esophageal Adenocarcinoma AJCC V8, Clinical Stage IV Gastric Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
11/28
11/28
NCT04164979: Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Active, not recruiting
2
20
US
Cabozantinib, CABOMETYX, COMETRIQ, Pembrolizumab, KEYTRUDA
University of California, Irvine, Exelixis
Gastric Adenocarcinoma, GastroEsophageal Cancer
11/23
12/24
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients With NET

Active, not recruiting
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
09/24
09/24
NCT04472767: Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Recruiting
2
35
US
Nivolumab, OPDIVO®, Ipilimumab, YERVOY®, Cabozantinib, CABOMETYX®, COMETRIQ, Transarterial Chemoembolization, TACE
University of California, Irvine, Exelixis
Hepatocellular Carcinoma, HCC
06/26
09/27
ETCTN 10476, NCT04941287: Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC 0973, GDC-0973, GDC0973, MEK Inhibitor GDC-0973, XL 518, XL-518, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Varlilumab, CDX 1127, CDX-1127, CDX1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer
National Cancer Institute (NCI)
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
01/24
07/25
NCT05724108: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Recruiting
2
94
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate, lutetium Lu 177-DOTATATE, Lutetium Oxodotreotide Lu-177, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811
National Cancer Institute (NCI)
Metastatic Neuroendocrine Tumor
03/25
03/25
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05117931: A Study of Amivantamab in People with Esophagogastric Cancer

Recruiting
2
25
US
Amivantamab
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Esophagogastric Cancer
11/25
11/25
MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting
1/2
129
US
MRG002
Shanghai Miracogen Inc.
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
10/22
12/24
NCT04068194: Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Recruiting
1/2
103
US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
12/25
12/25
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
ETCTN 10366, NCT04172532: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
1/2
98
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Placebo Administration
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
08/26
08/26
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Completed
1/2
31
Europe, US
NMS-01940153E
Nerviano Medical Sciences
Unresectable Hepatocellular Carcinoma (HCC)
01/24
08/24
NCT04074343: TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed
1
20
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11
University of California, Irvine, Taiho Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, GastroEsophageal Cancer
07/21
07/22
NCT04868773: Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting
1
12
US
Cabozantinib, CABOMETYX®, COMETRIQ, TAS-102, trifluridine and tipiracil
University of California, Irvine
Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer, CRC
08/23
02/25
NCT04920032: Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting
1
22
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11, Standard Treatment, Signatera MRD ctDNA Assay
University of California, Irvine, Taiho Pharmaceutical Co., Ltd., Natera, Inc.
Colon Adenocarcinoma, Colorectal Cancer
12/24
12/25
ETCTN 10402, NCT04514497: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Active, not recruiting
1
96
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
02/25
02/25
NCI-2022-04099, NCT05372614: Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Suspended
1
30
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Malignant Solid Neoplasm
06/25
06/25
NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Recruiting
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Emavusertib, AU 4948, AU-4948, CA 4948, CA-4948, CA4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948, IRAK4 Inhibitor CA-4948, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
03/25
03/25
NCT03863145: Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Recruiting
1
90
US
CB-03-10
Cosmo Technologies Ltd
Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
01/26
06/26
RANT-GC, NCT05733689: Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers ( Trial)

Not yet recruiting
1
20
US
ctDNA Blood Test, FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above)
University of California, Irvine, Natera, Inc.
Gastroesophageal Adenocarcinoma
02/26
02/26
DASH, NCT04704661: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The Trial

Recruiting
1
51
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Ceralasertib, AZD6738, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
03/26
03/26
Hernandez, Isela
ExTINGUSH, NCT04372615: The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Recruiting
2
116
Europe, US
Inebilizumab, UPLIZNA, Placebo
University of Utah
Autoimmune Encephalitis, Encephalitis
10/25
08/26
GRASP-01-002, NCT05257473: Defining Endpoints in Becker Muscular Dystrophy

Recruiting
N/A
80
Europe, US, RoW
Virginia Commonwealth University, Edgewise Therapeutics, Inc.
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
05/25
05/26
GRASP, NCT03981289: Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

Active, not recruiting
N/A
80
Europe, US
Virginia Commonwealth University, Newcastle University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Minnesota, University of California, Irvine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Colorado, Denver, University of Kansas Medical Center
Limb Girdle Muscular Dystrophy, Muscular Dystrophies
06/25
06/25
GRASP-01-003, NCT05618080: LGMD R1 Natural History Study

Recruiting
N/A
100
Europe, US
Virginia Commonwealth University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Florida, University of Minnesota, Newcastle University, University of Kansas Medical Center, University of Colorado, Denver, Indiana CHC (Community Health Clinic), University of California, Irvine
Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
05/28
08/28
Spolarich, Jessica
NCT05038150: Study of SGN1 in Patients With Advanced Solid Tumor

Recruiting
1/2
70
US, RoW
SGN1, SalMet-Vec
Guangzhou Sinogen Pharmaceutical Co., Ltd, ClinChoice Enterprise Management (Shanghai) Limited, Parexel
Advanced Solid Tumor
01/28
08/28
NCT06579391: Targeted Nutritional Supplement After Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial

Not yet recruiting
N/A
88
US
Essential amino acids, Alanine
University of California, Irvine, MEND
Lumbar Spinal Stenosis
09/25
07/26
Morenkova, Anna E
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Khurana, Sharad
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
MyeloMATCH, NCT05554406: Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A Treatment Trial)

Recruiting
2
335
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Echocardiography, EC, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
03/27
03/27
MyeloMATCH, NCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH ( Screening Trial)

Recruiting
2
2000
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Echocardiography, EC, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/29
05/29
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Checkmark First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Recruiting
1
50
US
Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/25
11/25
Karnes, William
RITUAL, NCT05732233: Ultivision AI CADe Randomized Controlled Trial

Terminated
N/A
137
Europe, Canada, US
Ultivision AI
Satisfai Health, Inc., Meditrial USA Inc.
Colon Adenoma, Polyp of Colon, Adenoma Colon
02/24
02/24
McCloud, Kaelyn
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis

Active, not recruiting
2/3
270
US, RoW
Ulviprubart (ABC008)
Abcuro, Inc.
Inclusion Body Myositis (IBM)
01/29
04/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)

No Longer Available
N/A
US
Pridopidine
Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Amyotrophic Lateral Sclerosis
 
 
CNMAu8.EAP02, NCT05281484: Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and for ALS

Available
N/A
US
CNM-Au8, Nanocrystalline gold
Clene Nanomedicine
Amyotrophic Lateral Sclerosis
 
 

Download Options